P157: Treatment of Cutaneous Hemangiomas with Topical Imiquimod 5%

Senchak, Andrew J.; Cable, Benjamin B.; Bessinger, G. Todd

doi:10.1016/j.otohns.2006.06.1191

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imiquimod is another topical medication, which has a modulatory effect on the immune response. However, it is indicated as a third-line therapeutic agent [43,46].…”

Section: Imiquimodmentioning

confidence: 99%

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

Luca¹,

Miron²,

Trandafir³

et al. 2021

Rom J Morphol Embryol

View full text Add to dashboard Cite

Infantile hemangiomas (IHs) are the most frequent pediatric benign vascular tumors, with a reported incidence of 5% to 10%. They have self-limiting evolution pattern divided into a growth phase in the first 12 months and a regression one, that may take up to 10 years. Occasionally, hemangiomas might lead to local or systemic complications, depending on their morphological characteristics. The first line of treatment is β-blockers, such as Propranolol, Timolol, Nadolol, administered either locally or systemically. Newer therapeutic strategies involving laser therapy and angiotensin-converting enzyme inhibitors are being studied, while older treatment modalities like corticosteroids, Imiquimod, Vincristine, Bleomycin and Interferon-α have become second line therapy options. Before establishing the appropriate treatment, clinical, histological, and imaging investigations are required.

show abstract

“…Imiquimod is another topical medication, which has a modulatory effect on the immune response. However, it is indicated as a third-line therapeutic agent [43,46].…”

Section: Imiquimodmentioning

confidence: 99%

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

Luca¹,

Miron²,

Trandafir³

et al. 2021

Rom J Morphol Embryol

View full text Add to dashboard Cite

show abstract

“…Vincristine is another therapeutic choice, currently preferred to IFN, in infants with life‐threatening cases non‐responders to corticosteroids treatment 89 . Imiquimod, a new topical agent, has been shown to accelerate the regression of proliferating IHs 17,90 . Potential efficacy of omega‐3 fatty acids in IHs has been hypothesized but more research is needed to determine the anti‐angiogenic properties of these acids 91 .…”

Section: Management and Treatmentmentioning

confidence: 99%

Infantile haemangiomas: a challenge in paediatric dermatology

Schwartz¹,

Sidor

Musumeci

et al. 2010

Acad Dermatol Venereol

View full text Add to dashboard Cite

Infantile haemangiomas, common benign vascular tumours of childhood, are characterized by rapid growth during the first year of life and a slow regression that is usually completed at 7-10 years of age. These tumours are composed of endothelial cells with high mitotic rates and stromal components such as fibroblasts, mast cells and pericytes. Haemangiomas become a challenge when they are part of a syndrome, are located in certain areas of the body or when complications develop. The above-mentioned factors also influence the treatment modality used. However, although there remain many uncertainties regarding management, the beta-adrenergic receptor blocker propranolol is a promising new candidate for first-line systemic therapy. It produces such a dramatic and rapid response that the appearance of an infantile haemangioma should impart expeditious consideration of the risks and benefits of its use.

show abstract

“…The most common tumors in infancy, of a vascular origin, are hemangiomas. The exact incidence may not be known; however, the reported incidence is ranging from 4% to 10% of the Caucasian infants [2][3][4][5] Most of the hemangiomas are occurring in a sporadic way and in some cases, the autosomal dominant pattern of familial transmission; has been also reported [6]. In a large series of 136 families having established infantile hemangiomas (IHs), about one-third of the patients have an associated family history; mostly among first-degree relatives [7].…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Imiquimod in the Treatment of Infantile Hemangioma; a Systematic Review and Meta-Analysis

Alakeel¹

2020

J Current Med Res Opinion

View full text Add to dashboard Cite

Objective: To study the safety and efficacy of imiquimod in the treatment of infantile hemangioma (IH). Method: Systematic search was conducted in nine electronic databases for selecting relevant articles reporting the safety and efficacy of imiquimod as a therapeutic agent for treatment of IH. Meta-analysis was used to pool the results. Results: Of total 180 records screened, we included 9 studies for this systematic review and meta-analysis. About one-fifth of the patients (20.9%) have showed clinical resolution with 95% confidence interval (CI) of 11.8% to 34.1%. Regarding IH type, superficial type showed the highest rates of both clinical resolution and excellent response rates with 31.2% (95% CI= 16.6% to 50.8%) and 26.5% (95% CI= 11.6% to 49.6%), respectively. A relatively high prevalence of any side effects with 63.1% (95% CI= 47.6% to 76.3%) has been reported. The highest reported side effect was crustation (44.1%; 95% CI= 27.8% to 61.8%). Conclusion: Imiquimod is effective in the treatment of superficial IH and it is associated with local side effects.

show abstract

P157: Treatment of Cutaneous Hemangiomas with Topical Imiquimod 5%

Cited by 4 publications

References 0 publications

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

Morphological, genetic and clinical correlations in infantile hemangiomas and their mimics

Infantile haemangiomas: a challenge in paediatric dermatology

Safety and Efficacy of Imiquimod in the Treatment of Infantile Hemangioma; a Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About